Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 34 for “"Budget Impact Analysis"”.

  1. Introducing Risperidone for Treatment of Schizophrenia to the Essential Drug List in Uganda: A Budget Impact Analysis

    … The aim of this study was to analyze the budget impact of introducing risperidone onto the essential drug list for treating schizophrenia in Uganda. Risperidone is a second-generation antipsychotic that has been shown to be cost-effective in a previous study in Uganda. More information on …

    washington Repository record for Introducing Risperidone for Treatment of Schizophrenia to the Essential Drug List in Uganda: A Budget Impact Analysis (opens in a new tab)

  2. Budget impact analysis of upadacitinib for the management of moderate-to-severe atopic dermatitis in patients treated with systemic therapies in the United States

    Objective: This study evaluated the budget impact of introducing upadacitinib for patients with uncontrolled moderate-to-severe atopic dermatitis (AD) from a United States (U.S.) private payer perspective. Methods: The model estimated costs before and after the adoption of upadacitinib for a …

    vcu Repository record for Budget impact analysis of upadacitinib for the management of moderate-to-severe atopic dermatitis in patients treated with systemic therapies in the United States (opens in a new tab)

  3. Proposals for Updating the Canadian Patented Medicine Prices Review Board Pharmaceutical Budget Impact Analysis Guidelines for New Drug Submissions to Public and Private Payers

    … Prices Review Board (PMPRB) 2007 pharmaceutical budget impact analysis (BIA) guidelines in accordance with the best national and transnational practices in BIA methodology and Canadian stakeholder feedback. Methods: National, transnational and Canadian federal, provincial and private BIA …

    mcmaster Repository record for Proposals for Updating the Canadian Patented Medicine Prices Review Board Pharmaceutical Budget Impact Analysis Guidelines for New Drug Submissions to Public and Private Payers (opens in a new tab)

  4. Cost utility and budget impact analysis of bortezomib and lenalidomide for the treatment of relapsed/refractory multiple myeloma in the South African public health sector

    … could potentially have significant economic impacts on the South African public health sector budget. The study suggests that one year of treatment for 337 RRMM patients in South Africa using the BORT and LEN/DEX would increase the budget budget-cost of RRMM treatment by 3136% and 8684%, …

    cape-town Repository record for Cost utility and budget impact analysis of bortezomib and lenalidomide for the treatment of relapsed/refractory multiple myeloma in the South African public health sector (opens in a new tab)

  5. Οικονομική αξιολόγηση νέας θεραπείας για την πολλαπλή σκλήρυνση: ανάλυση επίπτωσης στον προϋπολογισμό από την οπτική του ΕΟΠΥΥ / Economic evaluation of a novel therapy for multiple sclerosis: a budget impact analysis from the perspective of EOPYY

    … μοντέλο Ανάλυσης Επίπτωσης Προϋπολογισμού (Budget Impact Analysis, BIA) με χρονικό ορίζοντα πέντε ετών (2025–2029). Συγκεκριμένα, συγκρίθηκαν δύο σενάρια: το υφιστάμενο θεραπευτικό σενάριο, το οποίο περιλάμβανε τέσσερις ανωνυμοποιημένες θεραπείες (Θεραπεία A–D), και ένα μελλοντικό σενάριο, …

    athens Repository record for Οικονομική αξιολόγηση νέας θεραπείας για την πολλαπλή σκλήρυνση: ανάλυση επίπτωσης στον προϋπολογισμό από την οπτική του ΕΟΠΥΥ / Economic evaluation of a novel therapy for multiple sclerosis: a budget impact analysis from the perspective of EOPYY (opens in a new tab)

  6. Evaluation of data-driven methods for estimating uptake of new medicine

    Budget impact analysis (BIA) is a type of economic analysis that assesses the financial consequences of adopting a new health care intervention. It is designed to estimate the potential financial impact of the adoption and diffusion of new interventions within a given health system or setting, …

    lshtm Repository record for Evaluation of data-driven methods for estimating uptake of new medicine (opens in a new tab) Download PDF for Evaluation of data-driven methods for estimating uptake of new medicine (opens in a new tab)

  7. Ανάλυση επίπτωσης στον προυπολογισμό της Tαλαζοπαρίμπης (talzenna) για τη θεραπεία ενηλίκων ασθενών με μεταλλάξεις BRCA 1/2 και HER2-αρνητικό τοπικά προχωρημένο ή μεταστατικό καρκίνο. A budget impact analysis of talazoparib (Talzenna) for the treatment of adult patients with Germline BRCA 1/2 Mutations and HER2-Negative locally advanced or metastatic breast cancer in Greece

    … μοντέλο ανάλυσης επίπτωσης στον προϋπολογισμό (Budget Impact Model – BIM) σε Microsoft Excel, σύμφωνα με τις κατευθυντήριες οδηγίες της International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Η ανάλυση πραγματοποιήθηκε από την οπτική του δημόσιου πληρωτή (ΕΟΠΥΥ) με χρονικό …

    athens Repository record for Ανάλυση επίπτωσης στον προυπολογισμό της Tαλαζοπαρίμπης (talzenna) για τη θεραπεία ενηλίκων ασθενών με μεταλλάξεις BRCA 1/2 και HER2-αρνητικό τοπικά προχωρημένο ή μεταστατικό καρκίνο. A budget impact analysis of talazoparib (Talzenna) for the treatment of adult patients with Germline BRCA 1/2 Mutations and HER2-Negative locally advanced or metastatic breast cancer in Greece (opens in a new tab)

  8. Economic evaluation of capivasertib as a second-line therapy for advanced breast cancer

    … about its cost-effectiveness and financial impact. My thesis provides the first evidence to address these questions. Methods: First, we conducted a cost-effectiveness analysis to assess whether the approved combination of capivasertib with fulvestrant for either all patients or only …

    manitoba Repository record for Economic evaluation of capivasertib as a second-line therapy for advanced breast cancer (opens in a new tab)

  9. Cost-effectiveness of patient-matched pre- and on-treatment biomarkers in cancer therapy response prediction

    … Moreover, this study includes a decision and budget impact analysis of OncotypeDX after its introduction in Edinburgh’s Breast Clinic. RESULTS: Treatment-decision strategies that utilize EER4 are likely to be cost-effective. Specifically, EER4 in conjunction with PREDICT shows lower costs and …

    edinburgh Repository record for Cost-effectiveness of patient-matched pre- and on-treatment biomarkers in cancer therapy response prediction (opens in a new tab)

  10. Τime to market access of innovative medicines for metastatic lung cancer: the case of Greece. Potential facilitators and barriers.

    … υγείας. Η ανάλυση επιπτώσεων στον προϋπολογισμό (Budget Impact Analysis) παρουσιάστηκε σύμφωνα με τη πρότυπη μεθοδολογία του NICE. Αποτελέσματα: Oι μελέτες της οικονομικής ανάλυσης για τις θεραπείες με μονοκλωνικά αντισώματα κατέδειξαν ότι τα ποσά της δαπάνης τους επηρεάζουν τον προυπολογισμό και …

    athens Repository record for Τime to market access of innovative medicines for metastatic lung cancer: the case of Greece. Potential facilitators and barriers. (opens in a new tab)

  11. Scaling up early childhood development programs in low- and middle-income countries: understanding the determinants of scaling up early childhood development in Zambia

    … transcripts were analyzed using thematic analysis according to the framework method. A budget impact analysis (BIA) was conducted using prospectively collected program cost and implementation data supplemented by online sources and interviews with program staff. The total cost of scale-up …

    bu Repository record for Scaling up early childhood development programs in low- and middle-income countries: understanding the determinants of scaling up early childhood development in Zambia (opens in a new tab)

  12. Discrete-event simulation based resource modelling in Health Technology Assessment

    … health technologies. Economic evaluation and budget impact analysis are the two economic analyses currently feeding into HTA, typically within a deliberative framework. Whilst these analyses address efficiency and affordability, the issues of implementation and feasibility are typically …

    whiterose Download file for Discrete-event simulation based resource modelling in Health Technology Assessment (opens in a new tab)

  13. Evaluation of a Virtual Care Program for Unattached Patients in Southeastern Ontario

    … populations. A quantitative study assessing the budget impact of the virtual/hybrid care program for 872 unattached patients in Ontario found that the delivery of virtual/hybrid care for unattached patients could reduce emergency department visits and inpatient hospitalizations by 21% and 27.7%, …

    queens Repository record for Evaluation of a Virtual Care Program for Unattached Patients in Southeastern Ontario (opens in a new tab)

  14. Comparing manufacturer submitted analysis and Common Drug Review reanalysis of results: A review of health technology assessment reports for non-oncology medications from 2018 to 2019

    … differences between the manufacturer's submitted analysis and the Canada's Common Drug Review (CDR) economic reanalysis is a crucial step toward creating more appropriate models by manufacturers. We compared manufacturers’ submitted analysis to CDR reanalysis in order to identify any variations in …

    mcmaster Repository record for Comparing manufacturer submitted analysis and Common Drug Review reanalysis of results: A review of health technology assessment reports for non-oncology medications from 2018 to 2019 (opens in a new tab)

  15. Data science for health technology appraisal: data intelligence for the better evaluation of new treatments for breast cancer

    … in advanced breast cancer (ABC). Existing budget impact (BI) assessments, such as those provided by the Scottish Medicines Consortium (SMC), often rely on assumptions and expert opinion, failing to capture the complexity of real-world decision-making. This can result in either over- or …

    edinburgh Repository record for Data science for health technology appraisal: data intelligence for the better evaluation of new treatments for breast cancer (opens in a new tab)

  16. Assessment and stratification of women with hypertension in the second half of pregnancy: a clinical, biochemical, economical and outcome evaluation

    … Data from 100 women were then used to perform a budget impact analysis. A hypothetical decision analytical model using data extracted from case note review and reference cost tariffs, suggested a mean cost saving associated with the PlGF test (in the PlGF plus management arm) of £35,087 (95% CI …

    kings Repository record for Assessment and stratification of women with hypertension in the second half of pregnancy: a clinical, biochemical, economical and outcome evaluation (opens in a new tab) Download PDF for Assessment and stratification of women with hypertension in the second half of pregnancy: a clinical, biochemical, economical and outcome evaluation (opens in a new tab)

  17. The Need, Value and Affordability of First-line Treatments for Hip and Knee Osteoarthritis in Alberta

    … managing hip and/or knee OA; 3) Estimate the budget impact of funding GLA:D® for people with hip and knee OA waiting for total joint replacement (TJR) consultation in a universal publicly insured healthcare system. We surveyed 250 people over the telephone and found that only 20% of people …

    calgary Repository record for The Need, Value and Affordability of First-line Treatments for Hip and Knee Osteoarthritis in Alberta (opens in a new tab)

  18. Pharmacoeconomic modelling for policy decision-making : the case of sofosbuvir for hepatitis C infection in South Africa

    … the cost-effectiveness, the public health impact and the budget impact of sofosbuvir, or sofosbuvir-containing regimens for hepatitis C in South Africa. The study design was founded on the concept of pharmacoeconomic modelling and the target population of this research project was patients …

    nwu-za Repository record for Pharmacoeconomic modelling for policy decision-making : the case of sofosbuvir for hepatitis C infection in South Africa (opens in a new tab)

  19. Economic Evaluation of a Point of Care Pharmacogenetic Test (CYP2C19) from an Ontario Perspective

    … preference expressed as willingness to pay, budget impact (BIA) analysis (aggregate Ontario hospitals, and Ontario Drug Formulary) and impact on productivity. Principles and good practice guidance as presented by the International Society for Pharmacoeconomic and Outcome Research Task force …

    toronto-retro Repository record for Economic Evaluation of a Point of Care Pharmacogenetic Test (CYP2C19) from an Ontario Perspective (opens in a new tab)

  20. Ökonomische Analyse und Bewertung integrierter Versorgungssysteme im Gesundheitswesen

    … Basis und Ausgangspunkt bilden hierbei konkret Budget Impact Analysen, die als ergänzendes Bewertungsinstrument gesundheitsökonomischer Evaluationen zunehmend an Bedeutung gewinnen. Der im Rahmen der Arbeit fallstudienbasiert entwickelte erweiterte Bewertungsansatz ermöglicht eine Betrachtung …

    fu-berlin Repository record for Ökonomische Analyse und Bewertung integrierter Versorgungssysteme im Gesundheitswesen (opens in a new tab)

Page 1 of 2